Benzinga | Jun 29, 2021 09:12AM EDT

Iovance Biotherapeutics' TIL Therapy Achieves ORR Of 21.4% In Pre-Treated Lung Cancer Patients

* Iovance Biotherapeutics Inc (NASDAQ:IOVA) has announced clinical data for its tumor-infiltrating lymphocyte (TIL) therapy LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC).

* The cohort enrolled patients that had progressed on prior immune checkpoint inhibitor (ICI) therapy, including patients with oncogene-driven tumors who received prior tyrosine kinase inhibitor therapy.

* The overall response rate (ORR) was 21.4% (n=28, one complete response, and five partial responses).

* Historically, ORRs of approximately 20% were reported with ICIs as second-line therapy in ICI-na?ve patients who progressed on front-line chemotherapy.

* Disease control rate (DCR) was 64.3% following one-time treatment with LN-145 monotherapy, including two responders with PD-L1 negative tumors.

* The median duration of response was not reached at a median study follow-up of 8.2 months.

* The treatment-emergent adverse event profile was consistent with the underlying disease and known adverse event profiles of non-myeloablative lymphodepletion and IL-2.

* Iovance will present additional data from the cohort at a medical meeting in the second half of 2021.

* The company also dosed the first patient in the registration-supporting IOV-LUN-202 Study in second-line mNSCLC.

* Price Action: IOVA shares are down 5.24% at $25.52 during the premarket session on the last check Tuesday.